Regenerative medicine company Orthocell Ltd
(ASX:OCC) has received an additional Singapore patent for its CelGro medical device.
CelGro is collagen-based used for soft tissue regeneration.
The Singapore patent relates to the company’s method of manufacture of novel bio-scaffolds. These bio-scaffolds are used to aid in the surgical repair of soft tissue injuries such as tendon, nerve, cartilage and bone – as well as the delivery of stem cells to the relevant surgical sites.
In addition to Singapore, Orthocell has also been granted patents in the US, Canada, China and New Zealand.
This morning, Orthocell shares are tracking 1.27% higher at 40 cents.
